BH.IMMUN&BIO | DIVIS LABORATORIES | BH.IMMUN&BIO/ DIVIS LABORATORIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -7.8 | 77.2 | - | View Chart |
P/BV | x | 1.5 | 8.4 | 18.4% | View Chart |
Dividend Yield | % | 0.0 | 0.7 | - |
BH.IMMUN&BIO DIVIS LABORATORIES |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
DIVIS LABORATORIES Mar-23 |
BH.IMMUN&BIO/ DIVIS LABORATORIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 4,641 | 1.1% | |
Low | Rs | 21 | 2,730 | 0.8% | |
Sales per share (Unadj.) | Rs | 10.3 | 292.6 | 3.5% | |
Earnings per share (Unadj.) | Rs | -3.9 | 68.7 | -5.6% | |
Cash flow per share (Unadj.) | Rs | -3.8 | 81.6 | -4.7% | |
Dividends per share (Unadj.) | Rs | 0 | 30.00 | 0.0% | |
Avg Dividend yield | % | 0 | 0.8 | 0.0% | |
Book value per share (Unadj.) | Rs | 20.4 | 480.9 | 4.2% | |
Shares outstanding (eoy) | m | 43.18 | 265.47 | 16.3% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 12.6 | 27.8% | |
Avg P/E ratio | x | -9.4 | 53.7 | -17.5% | |
P/CF ratio (eoy) | x | -9.5 | 45.2 | -21.0% | |
Price / Book Value ratio | x | 1.8 | 7.7 | 23.1% | |
Dividend payout | % | 0 | 43.7 | -0.0% | |
Avg Mkt Cap | Rs m | 1,561 | 978,378 | 0.2% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 151 | 9,750 | 1.6% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 77,675 | 0.6% | |
Other income | Rs m | 11 | 3,447 | 0.3% | |
Total revenues | Rs m | 457 | 81,122 | 0.6% | |
Gross profit | Rs m | -161 | 23,691 | -0.7% | |
Depreciation | Rs m | 2 | 3,432 | 0.1% | |
Interest | Rs m | 71 | 20 | 360.2% | |
Profit before tax | Rs m | -223 | 23,686 | -0.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -56 | 5,453 | -1.0% | |
Profit after tax | Rs m | -166 | 18,234 | -0.9% | |
Gross profit margin | % | -36.0 | 30.5 | -118.1% | |
Effective tax rate | % | 25.3 | 23.0 | 109.8% | |
Net profit margin | % | -37.3 | 23.5 | -158.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 97,437 | 0.4% | |
Current liabilities | Rs m | 940 | 15,331 | 6.1% | |
Net working cap to sales | % | -130.6 | 105.7 | -123.5% | |
Current ratio | x | 0.4 | 6.4 | 6.0% | |
Inventory Days | Days | 85 | 8 | 1,019.7% | |
Debtors Days | Days | 1,135 | 842 | 134.8% | |
Net fixed assets | Rs m | 1,262 | 51,128 | 2.5% | |
Share capital | Rs m | 432 | 531 | 81.3% | |
"Free" reserves | Rs m | 450 | 127,140 | 0.4% | |
Net worth | Rs m | 882 | 127,671 | 0.7% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 1,620 | 148,565 | 1.1% | |
Interest coverage | x | -2.2 | 1,209.5 | -0.2% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.3 | 0.5 | 52.7% | |
Return on assets | % | -5.9 | 12.3 | -48.1% | |
Return on equity | % | -18.9 | 14.3 | -132.1% | |
Return on capital | % | -17.2 | 18.6 | -92.8% | |
Exports to sales | % | 0 | 85.7 | 0.0% | |
Imports to sales | % | 14.5 | 19.8 | 73.1% | |
Exports (fob) | Rs m | NA | 66,537 | 0.0% | |
Imports (cif) | Rs m | 65 | 15,378 | 0.4% | |
Fx inflow | Rs m | 0 | 66,537 | 0.0% | |
Fx outflow | Rs m | 65 | 15,715 | 0.4% | |
Net fx | Rs m | -65 | 50,822 | -0.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | 24,597 | 0.4% | |
From Investments | Rs m | 5 | -27,076 | -0.0% | |
From Financial Activity | Rs m | -147 | -7,972 | 1.8% | |
Net Cashflow | Rs m | -34 | -10,451 | 0.3% |
Indian Promoters | % | 59.3 | 51.9 | 114.1% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 36.9 | - | |
FIIs | % | 0.0 | 14.7 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.8 | 48.1 | 84.8% | |
Shareholders | 35,313 | 347,630 | 10.2% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BH.IMMUN&BIO With: SUN PHARMA CIPLA DR. REDDYS LAB ZYDUS LIFESCIENCES MANKIND PHARMA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BH.IMMUN&BIO | Divis Laboratories | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -2.43% | -0.13% | -0.26% |
1-Month | 6.26% | 12.68% | -0.36% |
1-Year | 31.57% | 23.56% | 53.37% |
3-Year CAGR | -11.55% | 0.93% | 14.81% |
5-Year CAGR | 31.47% | 18.19% | 19.73% |
* Compound Annual Growth Rate
Here are more details on the BH.IMMUN&BIO share price and the Divis Laboratories share price.
Moving on to shareholding structures...
The promoters of BH.IMMUN&BIO hold a 59.3% stake in the company. In case of Divis Laboratories the stake stands at 51.9%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BH.IMMUN&BIO and the shareholding pattern of Divis Laboratories.
Finally, a word on dividends...
In the most recent financial year, BH.IMMUN&BIO paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
Divis Laboratories paid Rs 30.0, and its dividend payout ratio stood at 43.7%.
You may visit here to review the dividend history of BH.IMMUN&BIO, and the dividend history of Divis Laboratories.
For a sector overview, read our pharmaceuticals sector report.
Asian stocks got off to a positive start on Monday ahead of the Federal Reserve's policy meeting later in the week.